Reports of Practical Oncology and Radiotherapy最新文献

{"title":"The prognostic value of selected indices combination in hepatocellular carcinoma patients treated with sorafenib.","authors":"Radosław Osmański, Marcin Mardas, Maria Litwiniuk, Marta Stelmach-Mardas","doi":"10.5603/rpor.111180","DOIUrl":"https://doi.org/10.5603/rpor.111180","url":null,"abstract":"<p><strong>Background: </strong>Considering a comprehensive approach to the hepatocellular carcinoma (HCC) patient's assessment, the aim of the study was to identify the clinical significance of selected indices as prognostic factors in HCC patients treated with sorafenib in daily clinical practice.</p><p><strong>Materials and methods: </strong>Out of 122 available HCC patients, 72 treated with sorafenib (800 mg per day) had their data analyzed. To assess nutritional status, liver condition and tumor burden, changes in the following indices were analyzed: body mass index (BMI), international normalized ratio (INR), the systemic inflammatory response index (SIRI), the platelet-to-lymphocyte ratio (PLR), the neutrophil-to-lymphocyte ratio (NLR), the model for end-stage liver disease (MELD), the albumin-bilirubin (ALBI), the prognostic nutritional index (PNI). Survival analyses were performed.</p><p><strong>Results: </strong>Significant differences were observed during treatment in body mass, BMI, monocyte, albumin, aspartate aminotransferase, bilirubin, SIRI, PNI and ALBI. Survival analyses revealed significant differences in progression-free survival (PFS) in median survival for: SIRI, NLR, ALBI, PNI and albumin (p < 0.001). For overall survival (OS), survival analyses revealed significant differences for albumin and PNI (p < 0.05). Cox regression for PFS and OS, adjusted for age, sex and BMI, revealed significant hazard ratios for albumin and for SIRI in PFS only.</p><p><strong>Conclusions: </strong>Albumin remains an important prognostic factor for both PFS and OS in HCC patients; however, new indices can be successfully used in clinical practice as valuable prognostic tools for PFS in patients with HCC treated with sorafenib.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"59-67"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volumetric regression of meningiomas following SRS and hFSRT - insights from long-term analysis.","authors":"Martin Palička, Marian Rybar, Jana Jackaninová, Lukáš Knybel, Stefan Reguli, Tomáš Blazek, Silvia Tomoszkova, Jakub Cvek","doi":"10.5603/rpor.109094","DOIUrl":"https://doi.org/10.5603/rpor.109094","url":null,"abstract":"<p><strong>Background: </strong>Meningiomas are the most common primary brain tumors in adults, typically managed with surgery, stereotactic radiosurgery (SRS), or hypofractionated stereotactic radiotherapy (hFSRT). While local control rates are high, volumetric regression dynamics and radiobiological parameters remain underexplored. This study evaluates meningioma regression after SRS and hFSRT and estimates the α/β ratio to refine radiotherapy strategies.</p><p><strong>Materials and methods: </strong>A retrospective analysis included 150 patients with intracranial meningiomas treated between 2010-2021. Volumetric assessment was performed for 62 lesions (1-10 cm³) treated with SRS (1 × 14 Gy) or hFSRT (3 × 7 Gy, 5 × 5 Gy, 5 × 6 Gy). Tumor volumes were measured pre-treatment and during follow-up using 3D MRI reconstruction. Radiobiological modeling and α/β calculation employed linear-quadratic (LQ) and linear-quadratic-linear (LQ-L) models.</p><p><strong>Results: </strong>SRS achieved significantly faster regression, with tumors shrinking by 32.7% at 2 years and 67.4% at 4 years, compared with 15.3% and 31.7% for hFSRT (p = 0.003). The α/β ratio was calculated at 3.15 Gy [95% confidence interval (CI): 3.07-3.23], refining understanding of meningioma radiobiology. Local control reached 91.3%, with comparable outcomes for SRS (91.4%) and hFSRT (91.3%). Symptomatic complications included brain edema (7.9%) and radiation necrosis (2.6%).</p><p><strong>Conclusion: </strong>CyberKnife SRS and hFSRT are effective and safe for meningiomas, though SRS induces faster volumetric regression (19% <i>vs</i>. 9% annual reduction for hFSRT). The α/β ratio of 3.15 Gy provides novel radiobiological insight, supporting more personalized treatment strategies.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"42-49"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose contribution from brachytherapy to the pelvic lymph nodal region during HDR image-guided brachytherapy - a study for rethinking modern volume-based planning.","authors":"Akkineni Naga Prasanthi, Anil Kumar Talluri, Lakshmi Venkataramana Puriparthi, Nvn Madhusudhan Sresty, Deleep Kumar Gudipudi","doi":"10.5603/rpor.109093","DOIUrl":"https://doi.org/10.5603/rpor.109093","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have evaluated nodal dose using Point-A prescriptions or variable dose rates. However, the impact of volume-based high-dose-rate (HDR) brachytherapy approaches remains less explored. In this study, we aimed to assess the dose contribution to the pelvic lymph nodes with volume-based (HR-CTV) prescription in comparison to point-A-based prescription during HDR brachytherapy in carcinoma cervix. This comparison has not been comprehensively evaluated in earlier literature, especially in the context of elective nodal contouring and HDR brachytherapy.</p><p><strong>Materials and methods: </strong>Thirty patients with carcinoma of the cervix [International Federation of Gynecology and Obstetrics (FIGO) stage IB2 or higher] were included for this retrospective study. Two plans were generated on each brachytherapy scan. The first plan (point-A-based) prescribed a dose of 7 Gy to point-A, while the second plan (HR-CTV-based) prescribed the dose to the HR-CTV. Dose volume histograms (DVH) parameters were compared between both the plans.</p><p><strong>Results: </strong>HR-CTV-based plans registered safer doses to OARs. Both the plans showed noticeable dose contributions to the pelvic lymph node stations, particularly the obturator, internal iliac, and presacral stations, with the highest contribution observed in the obturator group. However, HR-CTV-based plans contributed lower doses to these nodal regions, approximately 1 Gy less to the internal iliac and obturator stations and 2 Gy less to the presacral station compared to point-A-based plans when D50 was considered.</p><p><strong>Conclusions: </strong>HR-CTV-based plans demonstrated recognizable dose contribution to lymph nodes, although lower than the contribution by point-A-based plans. However, this modest difference can be effectively compensated by optimizing the external beam radiotherapy (EBRT) dose while simultaneously maintaining safe organ at risk (OAR) doses.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"133-141"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective study on association of fatigue with dose to central nervous system structures in head and neck irradiation.","authors":"Anu George, M Lithika Lavanya, Ayesha Iqbal Maniyar, T R Arul Ponni","doi":"10.5603/rpor.109518","DOIUrl":"https://doi.org/10.5603/rpor.109518","url":null,"abstract":"<p><strong>Background: </strong>Fatigue is a common symptom in cancer patients accounting for 50-80% of patients and is multifactorial. Although many studies have focused on fatigue in head and neck cancer patients, studies on radiation dosimetric analysis of central nervous system (CNS) structures and their association with fatigue are rare. Hence, we have assessed patient-reported acute fatigue scores and correlated them with radiation dose received by brainstem, posterior fossa and pituitary.</p><p><strong>Materials and methods: </strong>Forty-two head and neck cancer patients receiving radiotherapy from October 2018 to March 2020 were analyzed for fatigue scores using a questionnaire. Posterior Fossa, Pituitary and Brainstem structures were delineated and dose received by them was correlated with fatigue scores.</p><p><strong>Results: </strong>Fatigue scores increased from 49 ± 12 at baseline to 78 ± 12 at the 6^th week of radiation treatment and reduced to 56 ± 18 at one month post treatment, but did not reach pre-treatment values. A statistically significant correlation was observed between posterior fossa D max and 6^th week fatigue scores; and brainstem D max and fatigue scores at one month post treatment.</p><p><strong>Conclusions: </strong>Doses to brainstem and posterior fossa should be assessed and kept as low as reasonably possible to minimize fatigue.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"81-87"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intentional internal high-dose policy in VMAT for stage III NSCLC with consolidation durvalumab - a retrospective study.","authors":"Kae Okuma, Tairo Kashihara, Yuko Nakayama, Koji Inaba, Tomoya Kaneda, Kana Takahashi, Madoka Sakuramachi, Ayaka Nagao, Akane Yoshiba, Hiroshi Igaki","doi":"10.5603/rpor.110097","DOIUrl":"https://doi.org/10.5603/rpor.110097","url":null,"abstract":"<p><strong>Background: </strong>Concurrent chemoradiotherapy followed by durvalumab is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). However, uniform radiation dose escalation has failed to improve outcomes due to increased toxicity. The intentional internal high dose policy (IIHDP) selectively escalates radiation dose within the tumor while sparing organs at risk (OARs). This study assesses the feasibility and clinical outcomes of IIHDP using volumetric modulated arc therapy (VMAT).</p><p><strong>Materials and methods: </strong>We retrospectively analyzed 280 patients treated with definitive VMAT from 2017 to 2024, divided into IIHDP (n = 112) and homogeneous dose distribution policy (HDDP; n = 168) groups. The primary endpoint was local recurrence control (LRC); secondary endpoints included overall survival (OS), progression-free survival (PFS), and toxicity. Receiver operating characteristic (ROC) analysis was used to evaluate planning target volume (PTV) volume as a predictor of LRC.</p><p><strong>Results: </strong>Median follow-up was 20.5 months. The 2-year LRC was 75% (IIHDP) and 72% (HDDP) (p = 0.296). In patients with large PTVs (≥ 373 cc), IIHDP showed a trend toward improved LRC, though not statistically significant. The 2-year OS was 75% in both groups. Durvalumab ≥ 6 months was a strong independent predictor of OS [p < 0.001; hazard ratio (HR) = 0.274]. Rates of grade ≥ 3 pneumonitis (2.7% <i>vs</i>. 3.6%, p = 0.490) and esophagitis (0% <i>vs</i>. 1.2%, p = 0.212) were similar across groups.</p><p><strong>Conclusions: </strong>IIHDP with VMAT appears feasible and safe in selected patients with stage III NSCLC, achieving favorable tumor control without added toxicity or interruption of durvalumab. Further prospective studies are warranted to validate its benefit and define optimal patient selection.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"124-132"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nodal status in predicting the outcome of treatment with definitive chemoradiation in patients with cervical cancer in FIGO IIIC1 and IIIC2 stages.","authors":"Marija Živković Radojević, Katarina Janković, Marko Folić, Marko Spasić, Vladan Marković, Dragan Lončar, Pavle Petković, Radiša Vojinović, Neda Milosavljević","doi":"10.5603/rpor.109848","DOIUrl":"https://doi.org/10.5603/rpor.109848","url":null,"abstract":"<p><strong>Background: </strong>The 2018 International Federation of Gynecology and Obstetrics (FIGO) classification redefined stage III of locally advanced cervical cancer into substages IIIC1 pelvic and IIIC2 para-aortic lymphadenopathy, ignoring the number and size of lymph nodes. The aim was to analyse of the volume burden influence of the primary tumor and pathological lymph nodes, on the three-year overall survival (OS) and progression free survival (PFS), in cervical cancer patients FIGO stages IIIC1 and IIIC2 treated with definitive chemoradiation.</p><p><strong>Materials and methods: </strong>A retrospective clinical study based on the analysis of three-year OS, PFS and factors that may influence the time to disease progression in cervical cancer patients in FIGO IIIC1 and IIIC2 stages treated from January 2020 to January 2024 with external beam radiotherapy (EBRT) with simultaneous integrated or sequential boost doses, brachytherapy and chemopotentiation at the Radiation Oncology Center of the UCC Kragujevac.</p><p><strong>Results: </strong>The study included 92 patients whose three-year OS was 68.5%, while PFS was 57.6%. The influence of age, comorbidity, belonging to stage IIIC1 or IIIC2, pathohistological tumor characteristics, number, total volume (GTVn) or the presence of a conglomerate of lymph nodes, tumor volume (GTVt), treatment duration over 56 days and radiotherapy technique on the length of PFS was examined. The length of PFS is influenced by treatment duration over 56 days, GTVn, number and conglomeration of lymph nodes, and EBRT dose (p < 0.05).</p><p><strong>Conclusions: </strong>The number and total volume of lymph nodes have a statistically significant effect on the length of PFS in FIGO stage IIIC1 and IIIC2 cervical cancer patients treated with definitive chemoradiation.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"96-106"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast solitary extramedullary plasmacytoma treated with combined systemic therapy and radiotherapy: diagnostic and therapeutic insights from a rare case.","authors":"Alexander Bennassi, Kamel Debbi, Lahcène Belaïdi, Fatima Zahra Bellefkih, Taoufik El Gnaoui, Karim Belhadj, Narjess Daikhi, Gabriele Coraggio, Yazid Belkacemi","doi":"10.5603/rpor.108614","DOIUrl":"https://doi.org/10.5603/rpor.108614","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"155-157"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole brain radiotherapy and simultaneous integrated boost: is it still a viable treatment for multiple brain metastases in the era of SRS?","authors":"Halil Cumhur Yıldırım, Nuri Kaydıhan, Ecem Demir, Deniz Azaklıoğlu, Fazilet Öner Dinçbaş","doi":"10.5603/rpor.108615","DOIUrl":"https://doi.org/10.5603/rpor.108615","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to determine the outcomes of whole brain radiotherapy (WBRT) + simultaneous integrated boost (SIB) treatment in patients with multiple brain metastases.</p><p><strong>Materials and methods: </strong>34 patients who were treated for multiple brain metastases with WBRT + SIB in two radiation oncology departments between 2014 and 2020 were evaluated retrospectively. Intracranial control and overall survival after radiotherapy (RT) were calculated with the Kaplan-Meier test. The prognostic factors of survival after RT were determined with Cox regression analysis.</p><p><strong>Results: </strong>The median age was 62 [interquartile range (IQR): 57-69] years. Median survival after cranial RT was 10 [95% confidence interval (CI): 7-13] months. One-year intracranial control probability after RT was 83%. Acute and late RT toxicity were observed in 2 patients. After 3 months of follow-up, 23 (68%) patients had complete/near complete response, 9 (26%) had partial response, and 2 (6%) had stable disease. In univariate analysis, the factors affecting survival after cranial RT were the presence of neurological symptoms (p = 0.003) and Karnofsky performance score (KPS, p = 0.001). The median survival of patients with and without neurological symptoms was 5 (95% CI: 4-6) months and 16 (95% CI: 5-27) months. Median survival of patients with KPS 60, 70, 80, and 90 were 1, 5, 10 and 13 months, respectively. In multivariate analysis, the only statistically significant prognostic factor was KPS [hazard ratio (HR): 0.94 95% CI: (0.89-0.99), p = 0.031].</p><p><strong>Conclusions: </strong>WBRT + SIB is a well-tolerated technique with a promising 1-year intracranial control rate of 83% for patients with multiple brain metastases who were not amenable to surgery and/or SRS, particularly in good performance status (KPS > 70) and without neurologic impairments.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"25-33"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A competing TMPO-AS1-let-7b-5p-kinesin superfamily RNA network predicts poor lung cancer patient survival.","authors":"Sakshi Priya Kousik, Jagriti Singh, Prerna Vats, Bhavika Baweja, Chainsee Saini, Rajeev Nema","doi":"10.5603/rpor.108659","DOIUrl":"https://doi.org/10.5603/rpor.108659","url":null,"abstract":"<p><strong>Background: </strong>The high morbidity and mortality rates of lung cancer associated with smoking underscore the need for a deeper understanding of prognosis-related kinesin family-microRNA-long non-coding RNA-competitive endogenous RNA (KIFs-miRNA-lncRNA-ceRNA) networks.</p><p><strong>Materials and methods: </strong>Survival analysis was performed using Kaplan-Meier (KM) Plotter (log-rank test, p < 0.05), while differential expression was analyzed using The University of ALabama at Birmingham CANcer data portal (UALCAN), On-coDB, Gene Expression Profiling Interactive Analysis (GEPIA), and The Encyclopedia of RNA Interactomes (ENCORI) databases (|log₂FC|>1). Transcription factor analysis was conducted using Enrichment Analysis Resource (Enrichr), and the microRNA Network (miRNet) database was used to construct the ceRNA network. The miRWalk and RNA22 databases predicted folding energy and binding affinities between <i>KIF</i> genes and miRNAs. Additionally, molecular docking was performed to evaluate the binding affinities of KIF proteins with natural compounds, chemotherapeutic agents, and carcinogenic inducers.</p><p><strong>Results: </strong><i>KIF18B</i>, <i>KIF20A</i>, <i>KIF2C</i>, <i>KIF4A</i>, and <i>KIFC1</i> were significantly upregulated in lung cancer, particularly in lung adenocarcinoma (LUAD) (p < 0.05), and strongly associated with poor survival [hazard ratio (HR) = 1.5-2.0]. Transcription factor analysis revealed eukaryotic transcription factor 1 (E2F1) as a potential key regulator. These genes showed positive correlations with long non-coding RNA (lncRNA) thymopoietin antisense transcript 1 (TMPO-AS1) (R = 0.6) and negative correlations with miRNA homosapiens microRNA family (hsa-let-7b-5p) (R = -0.4 to -0.3). Targeting this regulatory axis, especially by enhancing hsa-let-7b-5p expression, could improve patient prognosis and suppress aggressive tumor growth. Strong folding energies were observed between <i>KIF</i> genes and hsa-let-7b-5p (-15.2 to -18.4 kcal/mol), while docking analysis demonstrated higher binding affinities of natural compounds compared to conventional chemotherapeutic agents.</p><p><strong>Conclusions: </strong>Our findings identify the KIF18B/KIF20A/KIF2C/KIF4A/KIFC1/TMPO-AS1/E2F1/hsa-let-7b-5p regulatory axis as a potential therapeutic target in LUAD, particularly among high-risk smokers. This suggests that its regulatory mechanisms could lead to new targeted therapies.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"1-17"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes of patients with advanced ovarian cancer receiving more than three cycles of neoadjuvant chemotherapy followed by interval cytoreductive surgery.","authors":"Hanady Hegazy","doi":"10.5603/rpor.110814","DOIUrl":"https://doi.org/10.5603/rpor.110814","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to describe survival outcomes in patients with advanced ovarian cancer according to the number of neoadjuvant chemotherapy (NACT) cycles received and to explore their relation to cytoreduction and pathological response.</p><p><strong>Materials and methods: </strong>The study included 70 patients with advanced ovarian cancers presented to our center receiving neoadjuvant chemotherapy followed by interval debulking surgery and continuation of adjuvant treatment. Files of these patients were reviewed and data were extracted. Patients' outcomes were determined in terms of progression free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>The median age was 59 years. Median PFS and OS was 33 months. Univariate PFS and OS analysis revealed that optimal cytoreduction and achieving pathological complete response (PCR) significantly reduced the hazard of progression and death. However, the time interval between the end of NACT and surgical debulking and the number of adjuvant chemotherapy cycles received didn't affect the PFS or OS significantly. In multivariate analysis of PFS and OS, it was found that achieving PCR significantly affect the survival outcomes and is considered as independent prognostic and predictive factor for PFS and OS. The rate of optimal cytoreduction was significantly correlated with the number of NACTx cycles received.</p><p><strong>Conclusions: </strong>Our study suggests that increased number of neoadjuvant chemotherapy cycles in patients with advanced ovarian cancer don't adversely affect the survival outcomes and that the rate of optimal cytoreduction and achieving PCR significantly affect patients' survival outcomes. Rate of optimal cytoreduction significantly increased with the increased number of neoadjuvant chemotherapy received. Keywords: Ovarian cancer, neoadjuvant chemotherapy, interval debulking, optimal debulking.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"31 1","pages":"18-24"},"PeriodicalIF":2.0,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}